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Orexin neuropeptides influence multiple homeostatic functions and play an essential
role in the expression of normal sleep-wake behavior. While their two known receptors
(OX1 and OX2 ) are targets for novel pharmacotherapeutics, the actions mediated by each
receptor remain largely unexplored. Using brain slices from mice constitutively lacking
either receptor, we used whole-cell and Ca2+ imaging methods to delineate the cellular
actions of each receptor within cholinergic [laterodorsal tegmental nucleus (LDT)] and
monoaminergic [dorsal raphe (DR) and locus coeruleus (LC)] brainstem nuclei—where
−/−
orexins promote arousal and suppress REM sleep. In slices from OX2 mice, orexin-A
(300 nM) elicited wild-type responses in LDT, DR, and LC neurons consisting of a
depolarizing current and augmented voltage-dependent Ca2+ transients. In slices from
−/−
OX1 mice, the depolarizing current was absent in LDT and LC neurons and was
attenuated in DR neurons, although Ca2+ -transients were still augmented. Since orexin-A
produced neither of these actions in slices lacking both receptors, our findings suggest
that orexin-mediated depolarization is mediated by both receptors in DR, but is exclusively
mediated by OX1 in LDT and LC neurons, even though OX2 is present and OX2 mRNA
−/−
appears elevated in brainstems from OX1 mice. Considering published behavioral data,
these findings support a model in which orexin-mediated excitation of mesopontine
cholinergic and monoaminergic neurons contributes little to stabilizing spontaneous
waking and sleep bouts, but functions in context-dependent arousal and helps restrict
muscle atonia to REM sleep. The augmented Ca2+ transients produced by both
receptors appeared mediated by influx via L-type Ca2+ channels, which is often linked to
transcriptional signaling. This could provide an adaptive signal to compensate for receptor
loss or prolonged antagonism and may contribute to the reduced severity of narcolepsy in
single receptor knockout mice.
Keywords: laterodorsal tegmental nucleus, dorsal raphe nucleus, locus coeruleus, whole-cell patch-clamp
recording, Ca2+ signaling

INTRODUCTION
Orexin-A and Orexin-B, also called hypocretin-1 and -2, are two
hypothalamic neuropeptides (De Lecea et al., 1998; Sakurai et al.,
1998) that influence feeding, metabolism, arousal, reward, and
stress substrates in the CNS (for review, see Tsujino and Sakurai,
2009). The orexin system plays a particularly important role in
the normal expression of waking and sleep since its disruption
underlies the sleep disorder narcolepsy with cataplexy in humans
(Peyron et al., 2000; Thannickal et al., 2000) and produces a narcolepsy phenotype with unstable behavioral states, sleep attacks
and cataplexy-like motor arrests in animals (Chemelli et al., 1999;
Lin et al., 1999; Hara et al., 2001; Willie et al., 2003; Beuckmann
et al., 2004; Mochizuki et al., 2004; Kalogiannis et al., 2011).
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Orexin actions are mediated by two G-protein coupled receptors (Sakurai et al., 1998), termed orexin-1 (OX1 ) and orexin-2
(OX2 ) receptors, which have partly overlapping and widespread
expression patterns in the CNS (Trivedi et al., 1998; Hervieu
et al., 2001; Marcus et al., 2001). These receptors are attractive targets for the development of a range of novel therapeutic
agents with potential for treating sleep disorders, obesity, stressrelated disorders, and addiction. The first orexin-related drugs
to appear will be the dual orexin receptor antagonists (DORAs)
for the treatment of insomnia (Uslaner et al., 2013; Winrow and
Renger, 2013), but there is significant interest in developing single orexin receptor-specific antagonists (SORAs). However, much
remains unknown about the cellular actions of each receptor and
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the behavioral consequences of activation or inhibition of each
receptor at their many targets.
In this study, we focus on mesopontine cholinergic [laterodorsal tegmental nucleus (LDT)] and monoaminergic [dorsal raphe
(DR) and locus coeruleus (LC)] neurons, which participate in
a spectrum of functions that include the control of arousal and
sleep (Jones, 2005; Brown et al., 2012), the maintenance of motor
activity and muscle tone during arousal (Jacobs and Fornal, 1993;
Michelsen et al., 2007), the mediation of stress related actions
and adaptation (Lowry et al., 2005; Valentino and Van Bockstaele,
2008) and the stimulation of motivated behavior via projections
to midbrain dopamine systems (Maskos, 2008; Mena-Segovia
et al., 2008). These structures, and especially the LC, receive substantial orexinergic innervation (Peyron et al., 1998; Chemelli
et al., 1999; Nambu et al., 1999), and orexin terminals have been
shown to synapse upon tyrosine hydroxylase immunoreactive
neurons in LC (Horvath et al., 1999), cholinergic neurons in the
LDT (Cid-Pellitero and Garzón, 2011) and DR neurons (Del CidPellitero and Garzón, 2011). Evidence from in-situ hybridization
studies in rat (Marcus et al., 2001) indicate that moderate levels
of OX1 mRNA are expressed in LDT and DR while especially high
levels of OX1 mRNA are expressed in the LC. These studies also
found moderate levels of OX2 mRNA levels in the DR with lower
levels in the LDT and LC. Consistent with this innervation pattern
and receptor distribution, exogenously applied orexins directly
depolarize LDT (Burlet et al., 2002; Kohlmeier et al., 2008) and
related PPT (Kim et al., 2009) neurons, along with DR (Brown
et al., 2002; Liu et al., 2002; Kohlmeier et al., 2008) and LC neurons (Horvath et al., 1999; Ivanov and Aston-Jones, 2000; Li et al.,
2002; Hoang et al., 2003; Murai and Akaike, 2005) partly, by
activating a cation current. Orexin-A has also been shown previously to have a distinct modulatory role in the LDT and DR
by augmenting the Ca2+ influx mediated by L-type Ca2+ channels (Kohlmeier et al., 2008). However, the roles played by each
receptor in these actions are unknown.
Early studies of orexin receptors using heterologous expression
found that both receptors stimulate Ca2+ -release from intracellular stores (Sakurai et al., 1998; Smart et al., 1999) and activate
phospholipase C (PLC) (Lund et al., 2000; Holmqvist et al., 2002),
suggesting they are Gq coupled receptors. More recent studies
indicate these receptors can couple to multiple G-proteins and
therefore may utilize more diverse signaling cascades, however,
much less is known about the signaling targets of native orexin
receptors (for review see Kukkonen and Leonard, 2013). Evidence
from studies of brain slices or freshly dissociated neurons indicate that native orexin receptors mediate neuronal depolarization
from resting membrane potential by activating three classes of
effectors (for review see Leonard and Kukkonen, 2013): closure of
K+ channels (Ivanov and Aston-Jones, 2000; Hwang et al., 2001;
Bayer et al., 2002; Grabauskas and Moises, 2003; Hoang et al.,
2003, 2004; Ishibashi et al., 2005; Bisetti et al., 2006), forward activation of the electrogenic Na+ /Ca2+ exchanger (Eriksson et al.,
2001; Wu et al., 2002, 2004; Burdakov et al., 2003), activation of
a cation current (Brown et al., 2002; Yang and Ferguson, 2002,
2003; Murai and Akaike, 2005; Kohlmeier et al., 2008) and can elevate intracellular [Ca2+ ] (Van Den Pol et al., 1998; Van Den Pol,
1999; Uramura et al., 2001; Xu et al., 2002; Kohlmeier et al., 2004,
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2008; Ishibashi et al., 2005). Only limited information is available
about the particular receptors mediating these actions, especially
since receptor overlap is common and subtype-specific antagonists are lacking. Conclusions about native receptor function has
often relied upon the relative potencies of orexin-A and -B, based
on the high potency of orexin-A for both receptors and the ∼10fold lower potency of orexin-B for OX1 expressed in CHO cells
(Sakurai et al., 1998). However, agonist-based receptor determinations have numerous potential confounds (see Leonard and
Kukkonen, 2013) including differing stability of agonists, differing receptor levels and the possibility of biased agonism, as has
been proposed for expressed orexin receptors (Putula et al., 2011).
To avoid these potential limitations, we sought to determine
the actions of each receptor in LDT, DR, and LC neurons using
a genetic dissection approach: We examined the actions by each
receptor using whole-cell recording and Ca2+ imaging methods
in brain slices from knockout mice constitutively lacking either
receptor thereby allowing us to determine the functional capacity of each receptor in isolation. This revealed that OX1 and OX2
have both convergent and unique functions in LDT, DR, and
LC neurons. These findings have implications for understanding
the cellular functions of orexin receptors, the behavioral consequences of orexin signaling at these loci and some consequences
for using receptor specific antagonists as therapeutics.

MATERIALS AND METHODS
All procedures complied with National Institutes of Health (US)
and institutional guidelines (New York Medical College) for ethical use of animals and were approved by the New York Medical
College Institutional Animal Care and Use Committee (IACUC).
ANIMALS AND GENOTYPING

Brain slices for whole cell recordings were prepared from 14 to 32
day old C57BL6, background control (orexin receptor wild-type;
−/−
−/−
−/−
−/−
OxrWT), OX2 , OX1 , and OX1 /OX2 double knockout
(DKO) mice. In those cases where calcium imaging was being performed with the cell permeant fura-2AM, mice aged 9–15 days
old were utilized. Both male and female mice were used in this
study and receptor knockout mice were the offspring of breeders
that were both homozygous for the null alleles on mixed C57BL6
and 129SvEv genetic backgrounds. The OxrWT mice were bred
+/−
from the wild-type progeny of the OX2
parents used to make
−/−
−/−
−/−
the OX2
mice. The OxrWT, OX2 , OX1 , and DKO mice
have been described previously (Willie et al., 2003; Kalogiannis
et al., 2011; Mieda et al., 2011).
To confirm genotypes, tail biopsies were obtained during
slice preparation and subsequently analyzed by PCR. One set
of primers were used to determine if the mouse was either
a wild-type or knockout for each orexin receptor. The three
primers for OX1 consisted of a common primer (5 -CTCTTTC
TCCACAGAGCCCAGGACTC-3 ), a knockout primer (5 -TGA
GCGAGTAACAACCCGTCGGATTC-3 ) and a wild-type primer
(5 gCAAGAATGGGTATGAAGGGAAGGGC-3 ). The expected
product sizes were ∼320 base pairs for the wild-type allele
and ∼500 base pairs for the knockout allele. The three primers for
OX2 consisted of a common primer (5 -CTGGTGCAAATCCCC
TGCAAA-3 ), a knockout primer (5 -GGTTTTCCCAGTCAC
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GACGTTGTA-3 ) and a wild-type primer (5 -AATCCTTCTAGA
GATCCCTCCTAG-3 ). The expected product sizes were ∼620
base pairs for wild-type allele and ∼300 base pairs for the knockout allele. These two sets of primers for different orexin receptors
were processed separately. PCR amplification consisted of denaturation at 95◦ C for 8 min followed by 35 cycles of 94◦ C (30 s), 62◦ C
(30 s) and 72◦ C (1 min), followed by one cycle at 72◦ C for 10 min.
The result of each PCR reaction was then separated using a 2%
agarose gel, and the PCR product was visualized with ethidium
bromide.

Differential functions of orexin receptors

in DMSO to a stock concentration of 10 mM and delivered at
the final concentration of 10 μM in ACSF. Bisindolylmaleimide
I, HCl (Calbiochem, EMD Biosciences) was dissolved in DMSO
to a stock concentration of 5 mM. On the day of experiments
it was diluted in TTX-ACSF to a final concentration of 1 μM
and applied for 5 min prior to application of orexin. Final dilutions of these drugs were made immediately before application
and light exposure was minimized throughout preparation and
application.
Ca2+ IMAGING

BRAIN SLICES AND ELECTROPHYSIOLOGY

Brain slices (250 μm) were prepared using a Leica vibratome
(VT1000S) in ice-cold artificial cerebrospinal fluid (ACSF) which
contained (in mM): 121 NaCl, 5 KCl, 1.2 NaH2 PO4 , 2.7 CaCl2 ,
1.2 MgSO4 , 26 NaHCO3 , 20 dextrose, 4.2 lactic acid and was oxygenated by bubbling with carbogen (95% O2 and 5% CO2 ). Slices
containing the LDT, DR, or LC were incubated at 35◦ C for 15 min
in oxygenated ACSF, and were then stored at room temperature
in continuously oxygenated ACSF, until they were utilized for
recordings.
For recording, slices were placed in a submersion chamber
on a fixed-stage microscope (Olympus BX50WI) and superfused
(1–2 ml/min) with ACSF (23 ± 2◦ C). Regions for recording were
chosen from within the boundaries of the LDT, DR, or LC nuclei
determined using a 4X objective and brightfield illumination.
Neurons were then visualized with a video camera and DIC
optics using a 40X water immersion objective (Olympus; NA
0.8). Large to medium sized multipolar neurons were selected
for gigaseal recording in voltage clamp or current clamp mode
using an Axoclamp 2A or Axopatch 2A or 2B amplifier (Axon
Instruments). Borosilicate patch pipettes (2–5 MOhms; cat number 8050, AM systems) containing a solution of (in mM) 144
K-Gluconate, 0.2 EGTA, 3 MgCl2 , 10 HEPES, 0.3 NaGTP, 4
Na2 ATP. Biocytin (0.1%) with the Na-GTP added to the pipette
solution just before use.
DRUGS AND EXPERIMENTAL SOLUTIONS

Normal ACSF contained (in mM) 124 NaCl, 5 KCl, 1.2
NaH2 PO4 , 2.7 CaCl2 , 1.2 MgSO4 , 26 NaHCO3 and 10 dextrose
(295–305 mOsm). To block voltage-gated sodium channels and
fast synaptic potentials, the ACSF (DABST-containing) contained
the ionotropic receptor antagonists DNQX (15 μM, Sigma), APV
(50 μM, Sigma), bicuculline (10 μM, Sigma), and strychnine
(2.5 μM, Sigma) with TTX (500 nM, Alomone). To measure the
average orexin-A mediated post-synaptic current and its I-V relation in LDT and DR neurons, CsCl (2 or 3 mM) was added
to the DABST to block H-current and a low Ca2+ ACSF was
used to inhibit voltage-gated Ca2+ currents. [Ca2+ ] was buffered
to <20 μM by the addition of 2.7 mM EGTA (calculated with
Patcher’s Power Tools XOP for Igor Pro). Orexin-A (Sigma, USA;
Phoenix Pharmaceuticals, USA; American Peptides, USA; Peptide
international, USA) was dissolved in deionized water or physiological saline in 1 mM aliquots and frozen (−80◦ C). Aliquots
were dissolved in ACSF to a final concentration of 300 nM immediately before use. The L-type Ca2+ channel antagonist nifedipine
and agonist, Bay-K-8644 (Bay-K; Sigma, USA) were dissolved
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Fluorescence related to intracellular calcium concentration was
measured from neurons in slices that had been either individually filled with bis-fura-2 from patch pipettes or bulk-loaded
with fura-2AM. The patch solution for Ca2+ imaging contained
the potassium salt of bis-fura-2 (50 μM, Molecular Probes) dissolved in a solution containing (in mM) 144 K-gluconate, 3
MgCl2 , 10 HEPES, 0.3 NaGTP, and 4 Na2 ATP. Biocytin (0.1%)
or biotinylated Alexa-594 (25 μM; Invitrogen) was included in all
experiments for cell identification following slice fixation.
For bulk loading neurons with fura-2, slices from young mice
(P6-P17) were incubated in ACSF containing 15 μM fura-2AM
(Molecular Probes) prepared from a 3.3 mM stock of fura-2AM
in DMSO. Slices were incubated for 30 min at 36◦ C in a small
volume equilibrated with Carbogen (5% CO2 /95% O2 ). Slices
were then transferred to the recording chamber and rinsed for
at least 30 min to ensure de-esterification and temperature equilibration. After locating a recording region in the LDT, DR, or LC,
individual cells were imaged with the 40× water immersion lens.
Ca2+ transients were monitored by measuring the emission
at 515 nm resulting from excitation of fura-2 with 380 nm (F380 ;
71000 Chroma fura-2 filter set) from a shuttered 75W Xenon
light source. Optical recordings were made using a back illuminated, frame-transfer, cooled CCD camera system (EEV 57 chip,
Micromax System, Roper Scientific) that was controlled with custom software (TI Workbench) running on a Mac OS computer.
Images were either acquired discontinuously (every 1–4 s) with
the shutter closed between images (600 ms exposure) or continuously (∼50 ms/frame), with the shutter open for the entire epoch.
Changes in intracellular calcium concentration were inferred
from changes in delta F/F (dF/F) where F is the fluorescence at
rest within a ROI following subtraction of background fluorescence. dF is the change in fluorescence following subtraction of
the average F prior to stimulation. dF/F was usually corrected
for photobleaching. Since rises in [Ca2+ ] produce a decrease in
F380 with fura-2, all dF/F measures are inverted so positive-going
traces indicate elevation of [Ca2+ ]i .
IMMUNOCYTOCHEMISTRY

Recorded neurons were identified as cholinergic, serotonergic
or noradrenergic by using conventional immunocytochemistry
following slice fixation in 4% paraformaldehyde, cryoprotection
and re-sectioning at 40 μm on a freezing microtome. Filled neurons were visualized with avidin-Texas Red or Alexa-594 biocytin.
Cholinergic neurons in the LDT selectively co-localize the enzyme
neuronal nitric oxide synthase (nNOS; Vincent et al., 1983)
and were identified by immunolabeling for nNOS (1:400 rabbit
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polyclonal, Sigma, Cat N7280). Serotonergic neurons in the DR
were identified by immunolabeling for tryptophan hydroxylase
(TpH; 1:400 sheep polyclonal, Abcam, 3907 and Covance, PSH327P). Catecholamine neurons in the LC were identified by
immunolabeling for tyrosine hydroxylase (TH; 1:1000, rabbit
polyclonal, Abcam, Cat 112). For immunofluorescence, primary
antibodies were visualized with FITC or Alexa 488-labeled secondary antibodies. Following washing and mounting, cleared sections were imaged using appropriate filter sets with a CCD camera
(Coolsnap, Roper Scientific or QICam, QImaging) mounted on
an epi-fluorescence microscope (BX60; Olympus). For immunohistochemistry primary antibodies were visualized with biotinylated secondary antibodies and the tissue was processed with a
Vector ABC kit as per the manufacturer’s instructions and reacted
with Sigma’s FastDAB kit for 5 min (Sigma-Aldrich, St. Louis,
MO). The precipitation reaction was stopped with three rises of
PBS and the sections were mounted on slides and coverslipped.

ATCT-3 reverse: 5 -GTGACGGTGGTCAGCACGAC-3 (which
corresponds to pubmed genbank NM_198959, 1364-1547); OX2 α
forward: 5 -GAGACAAGCTTGCAGCACTGAG-3 reverse: 5 TGAGTCGGGTATCCTCATCATAG-3 ; OX2 β forward: 5 -GAG
ACAAGCTTGCAGCACTGAG-3 reverse: 5 -GGTCGGTCAATG
TCCAATGTTC-3 (Chen and Randeva, 2004; Chen et al., 2006).
Each sample was loaded in duplicate (Roche, Lightcycler RTPCR). Light cycler protocols for mRNA quantification consisted
of denaturation at 95◦ C (485 s), cycling 40 times at 94◦ C (5 s),
64◦ C (10 s), and 76◦ C (14 s). The same amount of total RNA was
loaded into each capillary tube for the lightcycler. The measured
starting amount of target mRNA was then normalized by the
amount of total RNA loaded. The mRNA/total RNA ratios were
subsequently compared between samples obtained from C57BL6,
−/−
−/−
OX1 , OX2 , DKO, and 129SvEv mice. Lightcycler products
were then visualized with ethidium bromide in 2% agarose gels to
confirm the presence of the RT-PCR target.

RNA ISOLATION FROM WHOLE BRAINSTEM

DATA ANALYSIS

−/−

−/−

To isolate RNA from whole brainstems, C57BL6, OX1 , OX2 ,
DKO, and 129SvEv mice were anesthetized and decapitated as for
brain slices. The brainstems were then rapidly dissected from the
whole brain starting ∼5 mm anterior to the superior colliculus to
the medulla, and the cerebellum was removed. The brainstems
were then flash-frozen in liquid nitrogen. Total RNA was isolated from the frozen tissue using the RNeasy Lipid Tissue Mini
kit (Qiagen). RNA quality and quantity was determined by the
A260/A280 ratio from the spectrophotometer.
Standards were generated from cDNA isolated from the
C57BL6 brainstem. The cDNA was loaded with primers of the
gene of interest and amplified using a conventional PCR for 35
cycles. The product was then run on a gel to determine the
specificity of the amplification. If there was a single band of
the predicted size, the concentration of the PCR product was
determined through spectrophotometry and serially diluted. This
technique was utilized with all the primers to create scales unique
for each gene of interest. These scales were used to correlate target
mRNA fluorescence to sample starting concentration. Scales were
created for OX1 and for each of the two splice variants of OX2
identified in mouse: OX2 α and OX2 β (Chen and Randeva, 2004;
Chen et al., 2006). OX1 mRNA scales ranged from 1.8 × 10−2 to
1.8 × 10−5 μg/ml. OX2 α mRNA scales ranged from 7.7 × 10−2 to
7.7 × 10−5 μg/ml. OX2 β mRNA scale ranged from 9.0 × 10−3
to 9.0 × 10−6 μg/ml.
LIGHT CYCLER REAL TIME PCR

A 20 μl volume of the RNA solution, with ∼1 μg of total RNA
from each sample was reverse transcribed using random primers
and the Improm II Reverse Transcription (RT) kit (Promega).
The samples were incubated with random primers for 5 min
at 70◦ C, 5 min at 4◦ C and 1 h at 37◦ C followed by 70◦ C for
15 min. The RT product was then aliquoted and stored at −20◦ C.
Two microliters of the RT product were loaded with SYBR
green I reagent, 25 mM MgCl2 and primers to a final volume of 20 μl. Primers for OX1 , OX2 α, and OX2 β were loaded
at a constant concentration (10 μM) for their respective runs
(Invitrogen). The following sequences were used to amplify
the genes of interest: OX1 forward: 5 -TGCCGCCAACCCTATC
Frontiers in Neuroscience | Neuropharmacology

Data analysis and figure preparation was done using Igor
Pro (Wavemetrics) software. Differences between means were
determined by paired or unpaired Student’s t-test or a One
Way ANOVA using MS excel or DataDesk 6 software (Data
Description, Inc). Non-parametric comparisons were conducted
utilizing Chi-Square analysis using excel or DataDesk 6 or the
Kolmogorov-Smirnov test using Igor Pro. Numerical results are
reported as mean ± SEM.

RESULTS
PRINCIPAL NEURONS IN THE LDT, DR, AND LC APPEAR NORMAL IN
OREXIN RECEPTOR NULL MICE

To determine if the absence of orexin receptors resulted in
gross anomalies in the development of brainstem cholinergic
and monoaminergic nuclei, we inspected immunohistochemically stained tissue sections through the LDT, DR, and LC.
We examined nNOS, TpH, and TH staining in sections from
C57BL6 mice (n = 2) and from mice lacking one or both receptors (n = 2 for each genotype). Figure 1 shows comparable tissue
sections through the LDT, DR, and LC from a C57BL6 mouse
(left column) and a DKO mouse (right column) stained for
nNOS (top row), TpH (middle row), and TH (bottom row).
Immunoreactivity appeared highly specific and the expected
pools of labeled neurons were observed in sections from each
genotype. No gross differences were observed in distribution of
stained neurons or in the range of cell shapes in any of the receptor knockouts. This suggests that mesopontine cholinergic and
monoaminergic neurons will be found in their expected locations and will be encountered at about the same rate in brain slice
experiments from normal and receptor knockout mice. Of course,
this qualitative observation does not rule out quantitative differences that might be present between knockout and wild type mice
(see Kalogiannis et al., 2010; Valko et al., 2013).
OREXIN-A PRODUCES COMPARABLE NOISY INWARD CURRENT IN
SLICES FROM C57BL6 AND HYBRID BACKGROUND CONTROL MICE

In our previous studies of orexin actions on LDT and DR
neurons, we conducted whole-cell recordings and Ca2+ imaging
using slices made from C57BL6 mice (Burlet et al., 2002;
December 2013 | Volume 7 | Article 246 | 4
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ACTIVATION OF OX1 PRODUCES INWARD CURRENT AND ENHANCED
Ca2+ TRANSIENTS IN LDT, DR, AND LC NEURONS

FIGURE 1 | Double orexin receptor knockout (DKO) mice showed
grossly normal distributions of brainstem cholinergic and
monoaminergic neurons. (A) nNOS immunolabeled sections through the
caudal LDT stained with DAB from a C57BL6 mouse (left) and a DKO
mouse (right). (B) TpH immunolabeled sections through the caudal DR
stained with DAB from a C57BL6 mouse (left) and a DKO mouse (right). (C)
TH immunolabeled sections through the LC stained with DAB from a
C57BL6 mouse (left) and a DKO mouse (right). Abbreviations: Aq,
Aqueduct; scp, superior cerebellar peduncle.

Kohlmeier et al., 2004, 2008). Since receptor null mice were on
C57BL6/129SvEv hybrid background, we initially examined the
ability of a bath application of orexin-A (300 nM) to evoke an
inward current from a holding potential of −60 mV in LDT
and DR neurons in slices from C57BL6 and background control mice (OxrWT). As expected, orexin-A activated a noisy
inward current in both nuclei and this current appeared identical in both strains. In the LDT, we recorded 16 neurons from
13 C57BL6 mice and 7 neurons from 6 OxrWT mice. There
was no difference in the mean current (C57BL6: −19.1 ± 2.4
pA; OxrWT: −15.2 ± 3.1 pA; P = 0.38) and there was no difference in the distribution of current amplitudes, including the
three C57BL6 and two OxrWT neurons that didn’t respond
(Kolmogorov-Smirnov test, P = 0.24). In the DR, we recorded 31
neurons from 22 C57BL6 mice and 16 neurons from 8 OxrWT
mice. There was no difference in the mean current from cells that
responded to orexin (C57BL6: −36.3 ± 2.9 pA; OxrWT: −36.9 ±
3.2 pA; P = 0.89) and there was no difference in the distributions, including the one C57BL6 and two OxrWT neurons
that didn’t respond (Kolmogorov-Smirnov test, P = 1). This suggests that the differences in genetic background of C57BL6 and
hybrid mice has little influence on the expression of orexin
currents.
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To test the ability of OX1 to sustain orexin signaling in the LDT,
−/−
DR, and LC, we recorded from slices made from OX2 mice and
compared the orexin responses obtained in these knockouts with
those in slices obtained from C57BL6 mice (Figure 2). In each
nucleus, we examined the ability of a bath application of orexinA (300 nM) to evoke an inward current from a holding potential
of −60 mV and to enhance the Ca2+ influx produced by a voltagestep from −60 to −30 mV.
−/−
In LDT neurons recorded from OX2 mice, orexin-A evoked
a slowly developing inward current, often with an increase in frequency and amplitude of sEPSPs (Figure 2A1 ; normal ACSF) that
appeared quite similar to the responses previously described in
nNOS+ LDT neurons (Burlet et al., 2002). We did not analyze
the increase in sEPSC frequency in detail, but we compared the
average magnitude of the slowly developing inward orexin current
recorded from a holding potential of −60 mV (low-Ca2+ DABSTcontaining ACSF with Cs). This post-synaptic depolarizing current was −40.7 ± 13.0 pA (n = 7) which was not statistically
different from the inward current measured from LDT neurons
in slices from C57BL6 mice recorded under identical conditions (32.8 ± 10.6 pA; n = 8; P > 0.05; Figure 2D1 ). Orexin-A
(300 nM) also enhanced the Ca2+ -transient evoked by a 5 s
voltage-jump from −60 to −30 mV by 30.4 ± 6.4% (n = 9/12)
−/−
in neurons from OX2
mice (Figure 2A2 ; DABST-containing
ACSF). The magnitude of this Ca2+ transient enhancement was
also not different from that measured in LDT neurons from
C57BL6 mice (31.1 ± 7.7%; n = 9/13; P > 0.05; Figure 2D2 ).
−/−
In DR neurons recorded in slices from OX2 mice, orexin A
(300 nM) also evoked a slow inward current (Figure 2B1 ; normal
ACSF) as observed previously (Brown et al., 2002; Liu et al., 2002;
Kohlmeier et al., 2008). These inward currents were not accompanied by increases in sEPSCs, as expected from a previous study
(Haj-Dahmane and Shen, 2005). The average amplitude of the
orexin-evoked slow inward current was −55.2 ± 14.4 pA (n =
8; low-Ca2+ DABST-containing ACSF with Cs). This was not
statistically different from the orexin-evoked current measured
from DR neurons in slices from C57BL6 mice under the same
conditions (88.0 ± 24.1 pA; n = 7; P > 0.05; Figure 2D1 ). In
the voltage-step paradigm, orexin-A (300 nM) also enhanced the
Ca2+ -transient evoked by steps from −60 to −30 mV by 32.3 ±
−/−
mice (Figure 2A2 ;
8.7% (n = 13/18) in neurons from OX2
DABST-containing ACSF) as reported in wild-type DR neurons
(Kohlmeier et al., 2008). This enhancement in neurons from
−/−
mice was also not different from that measured in DR
OX2
neurons from C57BL6 mice (28.6 ± 3.5, n = 9/14; P > 0.05;
Figure 2D2 ) recorded under the same conditions.
−/−
In LC neurons from OX2
mice, orexin-A (300 nM) produced a small, slow inward current (Figure 2C1 ; normal ACSF).
The average current evoked by orexin-A was 11.4 ± 1.2 pA (n =
28; DABST-containing ACSF) and was not different from the
average current measured from LC neurons in slices from C57BL6
mice under the same conditions (12.4 ± 1.8 pA; n = 12; P >
0.05; Figure 2D1 ). Orexin-A (300 nM) also produced a strong
enhancement of the Ca2+ transient evoked by a voltage step
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−/−

FIGURE 2 | Recordings from OX2 slices indicate that OX1 is sufficient
for orexin-mediated excitation and enhancement of voltage-dependent
Ca2+ transients in LDT, DR, and LC neurons. (A) Whole-cell voltage clamp
−/−
recording from LDT neurons in OX2 slices showed that 300 nM orexin-A
(Orx-A) still evoked an inward current with increased sEPSCs [holding
potential: −60 mV; (A1 ); normal ACSF] and also augmented the Ca2+
transients evoked by 5 s voltage-steps from −60 to −30 mV [(A2 );
DABST-containing ACSF]. (B) Voltage clamp recordings from DR neurons in
−/−
OX2 slices showed that orexin-A evoked an inward [holding
potential: −60 mV; (B1 ); normal ACSF] and augmented Ca2+ transients [(B2 );
DABST-containing ACSF]. (C) Voltage clamp recordings from LC neurons in
−/−
OX2 slices showed that orexin-A evoked an inward current [holding
potential: −60 mV; (C1 ); normal ACSF] and augmented Ca2+ transients [(C2 );

from −60 to −30 mV (Figure 2C2 ; DABST-containing ACSF)
in LC neurons. This enhancement was on average 27.2 ± 4.8%
(n = 11/17) and was not different from that obtained from LC
neurons from C57BL6 mice (50.19 ± 19.1%; n = 6/8; P > 0.05;
Figure 2D2 ) recorded under the same conditions. Collectively,
these data indicate that OX1 is sufficient to mediate two normal
actions of orexin on LDT, DR, and LC neurons: (1) post-synaptic
activation of a slowly developing inward current and (2) the
enhancement of voltage-dependent Ca2+ influx.
To determine if OX1 mediated these actions in principal neu−/−
rons from each nucleus, we processed brain slices from OX2
mice for immunocytochemistry to identify the transmitter phenotype of recorded neurons. In the LDT, we confirmed that
OX1 activation produced an inward current in six nNOS+
neurons and that OX1 activation enhanced the voltage-step
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DABST-containing ACSF]. In (A1 ,B1 ,C1 ), the horizontal bar indicates time of
300 nM orexin-A superfusion. In (A2 ,B2 ,C2 ), top traces show somatic
Ca2+ -dependent fluorescence (dF/F); Middle traces show whole-cell current;
Bottom traces show membrane voltage. Calibration bars indicate 2% dF/F,
200 pA, 30 mV, and 2 s. (D) Neither the orexin-evoked inward current nor the
orexin-enhanced voltage-dependent Ca2+ transients was different in neurons
−/−
from OX2 slices compared to wild-type slices. Comparison by nuclei of the
mean ± SEM of the post-synaptic inward current [(D1 ); LDT and DR recorded
in low-Ca2+ DABST-containing ACSF with Cs; LC recorded in
DABST-containing ACSF] and mean ± SEM of the Ca2+ transient
enhancement [(D2 ); DABST-containing ACSF] produced by orexin-A in
−/−
neurons recorded from OX2 slices and C57BL6 slices under the same
conditions.

evoked Ca2+ transient in four nNOS+ neurons. In the DR,
we confirmed that OX1 activation produced an inward current
in nine TpH+ neurons and enhanced the voltage-step evoked
Ca2+ transient in four TpH+ neurons. Similarly, in the LC,
we confirmed that OX1 activation produced an inward current in 24 TH+ neurons and enhanced the voltage-step evoked
Ca2+ transient in 2/4 TH+ neurons. Figure 3 illustrates examples of an nNOS+ neuron recorded in the LDT (Figure 3A),
a TPH+ neuron recorded in the DR (Figure 3B) and a TH+
neuron recorded in the LC. Each of these neurons showed
an OX1 -mediated inward current and an enhancement of the
Ca2+ transient evoked by voltage steps from −60 to −30 mV.
From these data we conclude that OX1 is sufficient to mediate major direct orexin actions on principal cells of these
nuclei.
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FIGURE 3 | Stimulation of OX1 alone is sufficient to produce inward
currents and augmented voltage-dependent Ca2+ transients in
nNOS+ LDT neurons (A), TpH+ DR neurons (B), and TH+ LC
neurons (C). Left column illustrates low-power fluorescent micrographs
of the recorded slices immunostained and visualized with an
Alexa-488-label (green) for nNOS in LDT (A), TpH in DR (B), and TH in

OX1 ACTIVATES A NOISY CATION CURRENT IN LDT AND DR NEURONS
AND ENHANCES Ca2+ TRANSIENTS MEDIATED BY L-TYPE Ca2+
CHANNELS IN LDT, DR, AND LC NEURONS

As noted above, previous studies of LDT and DR neurons indicate that a noisy non-selective cation current is an important
effector mediating the slow membrane depolarization produced
by orexin-A. We therefore examined the change in membrane
noise and the current-voltage relation of the current evoked
−/−
mice to determine if
in LDT and DR neurons from OX2
OX1 is competent to activate a similar current. Since current
evoked by orexin-A in LC neurons was quite small in our recordings, and since they did not show a similar increase in noise,
we did not further characterize their orexin currents. In both
−/−
LDT (Figure 4A1 ) and DR (Figure 4B1 ) neurons from OX2
mice, orexin-A (300 nM) produced an inward current that was
accompanied by a large increase in membrane current noise,
similar to that reported in wild-type mice (Kohlmeier et al.,
2008). The membrane current noise increased by 118.4 ± 59.3%
in LDT neurons (n = 8) and by 307 ± 87.0% in DR neurons
(n = 7) which was not different from values in LDT (86.8 ±
31.3%, n = 8; P > 0.05) and DR (380.5 ± 85.2%; n = 7; P >
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the LC (C). The second column illustrates a higher-power image of the
recorded and red fluorescently labeled neuron (arrow; Alexa 594) in
each nucleus. The third column shows the same field with Alexa 488
visualized. The right column merges the Alexa 488 and 594 images and
indicates that each recorded neuron was immunopositive for nNOS,
TpH, and TH, respectively.

0.05) from C57BL6 mice. Similarly, the I-V relation for the
orexin mediated current in LDT (Figure 4A2 ) and DR neu−/−
rons (Figure 4B2 ) from OX2 mice was computed from voltage
ramps between −100 and −35 mV. It appeared roughly linear over this range as previously described for C57BL6 neurons
in these nuclei (Kohlmeier et al., 2008) suggesting that OX1
activates the same channel or channels that are activated in
C57BL6 mice.
In LDT and DR neurons from C57BL6 mice, the orexin
mediated enhancement of voltage-dependent Ca2+ transients
produced by voltage-steps from −60 to −30 mV is produced
almost entirely by the enhancement of Ca2+ transients generated
by L-type Ca2+ channels (Kohlmeier et al., 2008). We therefore tested whether the L-channel antagonist nifedipine (10 μM),
also occludes this enhancement in LDT, DR, and LC neurons
in slices from OX2 mice. Nifedipine alone, attenuated the Ca2+
transient produced by a voltage-step from −30 to −60 mV in
LDT (Figure 4C), DR (Figure 4D), and LC (Figure 4E) neurons
indicating that activation of L-type channels contribute to these
transients. In the presence of nifedipine, orexin failed to significantly enhance the calcium transient in all cells examined

December 2013 | Volume 7 | Article 246 | 7

Kohlmeier et al.

FIGURE 4 | Stimulation of OX1 alone activates a noisy cation current in
LDT and DR neurons and enhance voltage-dependent Ca2+ transients
mediated by L-type Ca2+ channels in LDT, DR, and LC neurons. (A1 )
Holding current (at −60 mV; Ibase; bottom trace) and membrane current
noise (Irms; top trace) were measured every 30 s starting before bath
−/−
application of 300 nM orexin-A (horizontal bar) from LDT neurons in OX2
slices. Orexin produced an inward shift in holding current that was
accompanied by an increase in current noise. (A2 ). The I-V curve of the
orexin-evoked inward current (IOrx ) was obtained by subtracting the
membrane current produced by a voltage ramp between −100 and −35 mV
prior to orexin-A application from that obtained during the peak of the
orexin-A-evoked inward current. These currents were similar to those

within the LDT, DR, or LC (LDT: 9% reduction in the transient,
P > 0.05. n = 4; DR: 5.2% reduction in the transient, P > 0.05,
n = 4; LC: 1.8% increase in the transient, P > 0.05, n = 4). These
data suggest that the Ca2+ transients augmented by OX1 signaling
are mediated by enhanced influx via L-type Ca2+ channels. Thus,
activation of OX1 alone is sufficient to activate a noisy cation current in LDT and DR neurons and to enhance Ca2+ transients
which appear generated by L-type Ca2+ channels in the LDT, DR,
and LC.
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obtained from LDT neurons in C57BL6 slices. (B1 ) Orexin-A (300 nM) has a
similar, but larger effect on the holding current (Ibase, bottom) and membrane
−/−
current noise (Irms, top) in DR neurons recorded in OX2 slices. (B2 ) The I-V
relation for the orexin-evoked inward current (IOrx ) in a DR neuron from an
−/−
OX2 slice was similar that that observed in DR neurons from C57BL6
slices. (C,D,E). The L-channel antagonist, nifedipine (Nif, 10 μM) attenuated
the Ca2+ -transients evoked by voltage-steps from −60 to −30 mV in LDT (C),
−/−
DR (D), and LC (E) neurons from OX2 slices and completely blocked the
enhancement of these transients by orexin-A (300 nM). Top traces show
somatic Ca2+ -dependent fluorescence (dF/F); Middle traces show whole-cell
current; Bottom traces show membrane voltage. Calibration bar labels in (E),
also apply to (C) and (D).

ACTIVATION OF OX2 EXCITES DR NEURONS AND ENHANCES Ca2+
TRANSIENTS IN LDT, DR, AND LC NEURONS

To determine whether activation of OX2 alone can influence
membrane currents and Ca2+ transients in LDT, DR, and LC
neurons, we examined the action of orexin-A in slices prepared from mice lacking OX1 . Whole-cell recordings from LDT
(n = 14) and LC (n = 45) neurons revealed that in that absence
of OX1 , 300 nM orexin-A failed to induce a detectable inward
current at a holding potential of −60 mV (Figures 5A1 ,C1 ).
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FIGURE 5 | Stimulation of OX2 alone is sufficient to produce an inward
current in DR neurons and to enhance voltage-dependent Ca2+
transients in LDT, DR, and LC neurons. (A) Whole-cell voltage clamp
−/−
recordings obtained from LDT neurons in OX1 slices showed that 300 nM
orexin-A (Orx-A) failed to evoke a current at −60 mV (A1 ) but augmented
voltage-dependent Ca2+ transients evoked by 5 s voltage-steps from −60
to −30 mV (A2 ). (B) Voltage clamp recordings obtained from DR neurons in
−/−
OX1 slices showed that orexin-A evoked both a noisy inward current
(holding potential: −60 mV; B1 ) and augmented voltage-dependent Ca2+
transients (B2 ). (C) Voltage clamp recordings obtained from LC neurons in
−/−
OX1 slices showed that orexin-A failed to evoke an inward current (holding

In contrast, orexin-A application to DR neurons resulted in
significant inward current with a large increase in membrane
noise (Figure 5B1 ). Nevertheless, the average peak inward current elicited by orexin-A in DR neurons (32.2 ± 6.3 pA; n = 8)
was significantly lower than observed in control recordings from
DR neurons in slices from C57BL6 mice (88.0 ± 24.1 pA; n = 7;
P < 0.05; Figure 5D1 ).
Despite being unable to stimulate inward currents in LDT
−/−
and LC neurons from OX1
mice, orexin-A was effective at
2+
enhancing Ca transients evoked by voltage-jumps from −60
to −30 mV in LDT, DR and LC neurons (Figures 5A2 ,B2 ,C2 ).
In fact, on average the magnitude of the enhancement in the
absence of OX1 (LDT: 50.6 ± 9.0%, n = 7/17; DR: 36.5 ± 10.4,
n = 11/18; LC: 37.3 ± 5.5, n = 8/13) was as large as observed
in control neurons from C57BL6 mice (Figure 5D2 ; P > 0.05
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potential: −60 mV; C1 ) but augmented voltage-dependent Ca2+ transients
(C2 ). In (A1 ,B1 ,C1 ), the horizontal bar indicates time of 300 nM orexin-A
superfusion. In (A2 ,B2 ,C2 ), Top traces show somatic Ca2+ -dependent
fluorescence (dF/F); Middle traces show whole-cell current; Bottom traces
show membrane voltage. Calibration bars indicate 2% dF/F, 200 pA, 30 mV
and 2 s. (D) The orexin-A evoked inward current was absent in LDT and LC
−/−
neurons and was significantly smaller in DR neurons from OX1 slices than
in DR neurons from C57BL6 slices (D1 ; ∗ P < 0.05). In contrast, the
magnitude of the Ca2+ transient enhancement produced by orexin-A was the
−/−
same in LDT, DR, and LC neurons from OX1 slices compared to those
recorded in C57BL6 slices.

for each cell type). In a some recordings, we were able to verify that the recorded neurons were nNOS+ in the LDT (n =
6), TpH+ in the DR (n = 9), and TH+ in the LC (n = 13;
Figure 6). This confirmed that OX2 alone is insufficient to excite
neurons in the LDT and LC at subthreshold membrane potentials but is sufficient to do so in TpH+ DR neurons. In spite
of this, OX2 activation is able to augment the step-activated
Ca2+ transients in principal neurons of each of these nuclei.
This implies that released orexin would enhance Ca2+ influx
during persistent activity in each nucleus, even in OX1 null
mice.
We also examined the I–V relation between −100 and −30 mV
in LDT and DR neurons. This confirmed that no observable subthreshold currents were activated by orexin-A in LDT neurons
(Figures 7A1 ,A2 ) and that the noisy inward current activated in
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FIGURE 6 | Orexin augments voltage-dependent Ca2+ transients in
nNOS+ LDT neurons, TpH+ DR neurons, and TH+ LC neurons in
−/−
mice. Orexin-A augmented the voltage-dependent
slices from OX1
Ca2+ transient in identified neurons. Left column illustrates low-power
fluorescent micrographs of the recorded slices immunostained with
Alexa-488 (green) for nNOS in LDT (A), TpH in DR (B), and TH in the

DR neurons was approximately linear over this voltage range,
having similar characteristics to the non-selective cation current
observed in C57BL6 DR neurons (Figures 7B1 ,B2 ). Similarly, we
determined whether L-type Ca2+ channels are a target of OX2
by testing whether nifedipine occluded the orexin-A enhancement of Ca2+ transients (Figures 7C,D,E). In LDT, DR, and LC
neurons obtained from mice lacking OX1 , nifedipine blocked
the enhancement produced by orexin-A (300 nM) application.
In the presence of nifedipine, orexin-A application produced a
0.6 ± 0.4% increase in LDT (n = 4), a 4.0 ± 2.1% increase in DR
(n = 5) and a 3.6 ± 3.3% increase in LC neurons (n = 6). These
changes were not significantly different from zero (P > 0.05) and
all of these differences were significantly less than changes produced in neurons from C57BL6 mice (P < 0.05). Thus, activation
of OX2 alone is sufficient to activate a noisy cation current in DR
neurons but not in LDT or LC neurons. Despite this, OX2 activation is sufficient to enhance Ca2+ transients in the LDT, DR, and
LC. Moreover, the magnitude of this enhancement was comparable to the enhancement measured in LDT, DR, and LC neurons
from C57BL6 mice and also appear mediated by L-type Ca2+
channels.
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LC (C arrows). The second column illustrates a higher-power image of
the recorded and fluorescently labeled neurons (Alexa-594) from each
nucleus. The third column shows the same field with Alexa-488
visualized. The right column shows the images merged, revealing that
each recorded neuron was immunopositive for nNOS, TpH, and TH,
respectively.

OX1 SIGNALING IS DOMINANT IN THE LDT AND LC BUT IS MORE
EVENLY SHARED BY BOTH RECEPTORS IN THE DR

To obtain a better estimate of the fraction of neurons activated by each orexin receptor, we utilized fura-2AM loading
of slices obtained from mice lacking each receptor (Figure 8).
Under these conditions, orexin-A (300 nM) evokes Ca2+ transients by both depolarization and subsequent activation of a
voltage-dependent Ca2+ influx and by specific enhancement of
the Ca2+ transient evoked by L-type Ca2+ channel activation
(Kohlmeier et al., 2004, 2008). As expected from whole-cell Ca2+
transient measurements, 300 nM orexin-A evoked Ca2+ transients in slices obtained from mice lacking OX2 (Figure 8A) and
mice lacking OX1 (Figure 8B). We found that in each genotype
and nucleus, these transients recapitulated the range of temporal profiles we observed in DR and LDT slices from C57BL6 mice
(Kohlmeier et al., 2004). Moreover, when the magnitude of the
“plateau” type Ca2+ responses, which we could confidently measure, were compared, the transients from knockout slices were
not smaller than the transients from C57BL6 slices. In OX2 null
tissue, the average plateau responses were 11.9 ± 1.8% in LDT
(n = 13); 9.9 ± 1.9% in DR (n = 18); and 12.1 ± 2.4% in LC
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FIGURE 7 | Stimulation of OX2 alone activate a noisy cation current
in DR neurons and enhance Ca2+ transients mediated by L-type
Ca2+ channels in LDT, DR, and LC neurons. (A1 ) Whole-cell voltage
−/−
slice
clamp currents (upper traces) from an LDT neuron in an OX1
recorded before and after bath superfusion with orexin-A (Orx-A,
300 nM). These currents were produced by the voltage-ramp in the
bottom trace (−100 to −35 mV). Orexin failed to produce an inward
−/−
mice. (A2 ) The
shift in holding current in LDT neurons from OX1
difference between the currents in (A1 ) plotted as a function of
membrane voltage (Vm) shows the I-V relation. No orexin current was
detectable throughout the voltage range studied. (B1 ) Orexin-A (300 nM)

(n = 12), which were not different (P > 0.05) from responses
measured in slices from C57BL6 mice (11.0 ± 2.2% in LDT,
n = 29; 13.8 ± 2.6% in DR, n = 49; and 12.7 ± 2.3% in LC,
n = 24). Similarly, in OX1 null slices, the average plateau response
were not different (P > 0.05) from those in C57BL6 slices (OX1
null responses: 12.0 ± 4.3% in LDT, n = 12; 16.1 ± 2.5% in DR,
n = 15; and 15.1 ± 5.1% in LC, n = 5). However, the likelihood of encountering orexin-A responsive cells (Figure 8C) was
much lower in slices from OX1 null mice in both the LDT
and LC. The proportion of fura-2AM labeled cells responding to orexin was only 20% in LDT (n = 113) and 10% in
LC (n = 82) compared to estimates of 60–70% responding in
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produced an inward shift in holding current and a large increase in
−/−
membrane current noise in DR neurons recorded in OX1
slices. (B2 )
The I-V relation for the difference current from (B1 ) appeared nearly
linear and was characteristic of the cation current observed in DR
neurons from C57BL6 slices. (C,D,E) The L-channel antagonist, nifedipine
(Nif, 10 μM) attenuated the Ca2+ -transients evoked by voltage-steps from
−/−
−60 to −30 mV in LDT (C), DR (D), and LC (E) neurons from OX1
slices and prevented the enhancement of these transients by orexin-A
(300 nM). Top traces show somatic Ca2+ -dependent fluorescence (dF/F);
Middle traces show whole-cell current; Bottom traces show membrane
voltage. Calibration bar labels in (E), also apply to (C,D).

slices from C57BL6 mice. Interestingly, in the DR from OX1
null mice, the fraction of responders was only reduced to 47.1%
from about 70% in the C57BL6 mice. Presumably this high
percent responding in the DR reflects the ability of OX2 to
drive depolarizations in DR neurons unlike in LDT and LC
neurons.
OX1 AND OX2 SIGNALING IS ATTENUATED BY PKC INHIBITION

In the next series of experiments we examined whether the
PKC inhibitor Bis I attenuates the Ca2+ transients evoked by
activity of one or both receptors. In these experiments, we first
obtained control responses with bath application of orexin-A
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OREXIN ACTIONS IN THE LDT, DR, AND LC REQUIRE THE TWO KNOWN
OREXIN RECEPTORS

Interpretation of our data from single receptor knockouts presupposes that there are only two orexin receptors responsible
for orexin actions and that our test concentration of orexin-A
is specific for these receptors. We directly tested this by examining the action of orexin-A on slices made from mice lacking
both orexin receptors. As can be seen in Figure 10A, orexinA (300 nM) did not evoke Ca2+ transients in slices from DKO
mice. To verify that each of the cells recorded under these conditions remained viable, we followed orexin application with a
bolus application of glutamate (5 mM), which rapidly and effectively evoked Ca2+ transients in these same cells (Figure 10B). We
also examined extracellular recordings using cell-attached patch
recordings, whole-cell currents and the ability of orexin to augment the Ca2+ transients produced by step depolarizations to
−30 mV. In each of these tests, orexin-A failed to produce a
response. Collectively these data strongly indicate that 300 nM
orexin-A is specific for native orexin receptors and that OX1 and
OX2 are the only functional orexin receptors expressed in the
LDT, DR and LC.
WHOLE BRAINSTEM OX2 mRNA LEVELS ARE HIGHER IN MICE
LACKING OX1

FIGURE 8 | Orexin-A stimulates a larger fraction of LDT, DR, and LC
cells via OX1 than via OX2 . (A) Orexin-A (Orx-A, 300 nM) evoked Ca2+
−/−
transients in LDT, DR, and LC neurons in slices from OX2 mice that were
bulk-loaded with fura-2AM. (B) Orexin-A (300 nM) also evoked Ca2+
−/−
transients in LDT, DR, and LC neurons in slices from OX1 mice that were
bulk-loaded with fura-2AM. The magnitude of the transients evoked by
either receptor was not different from that evoked in slices from C57BL6
mice (see text). (C) In slices from C57BL6 mice, 60–70% of fura-2AM
labeled cells in LDT (n = 173), DR (n = 113), and LC (n = 98) were activated
by orexin. The percentage of cells imaged that responded to orexin-A in
−/−
slices from OX2 mice (LDT: n = 60; DR: n = 96; LC: n = 43) was not
statistically different from that in C57BL6 slices. A significantly smaller
percentage of cells imaged in each nucleus was activated by orexin in
−/−
slices from OX1 mice (LDT: n = 113; DR:n = 87; LC: n = 82). Horizontal
bars above the traces indicate application of orexin-A (300 nM). Calibration
bars indicate 10% dF/F and 2 min in each panel. ∗ P < 0.05.

−/−

−/−

(300 nM) from OX2
or OX1
slices containing LDT, DR,
or LC (Figures 9, left column in A,B). The slices were then
superfused with ACSF containing bis I (1 μM; Bis) for 20 min,
to inhibit PKC. This completely attenuated the orexin-mediated
enhancement of L-type Ca2+ transients but did not block the
orexin mediated depolarization in all LDT and DR neurons
(Kohlmeier et al., 2008). Here, we found that the Ca2+ transients
evoked in each nucleus were strongly attenuated by Bis in slices
from both OX2 and OX1 null mice (Figures 9, right column in
A,B). The average amplitude of plateau responses was reduced
by 62.0 ± 7.7% in slices from OX2 null mice (n = 34) and by
−/−
59.3 ± 8.3 in slices from OX1 mice (n = 25). Thus, Ca2+ transients evoked by activation of either orexin receptor involves PKC
signaling.
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A potential complication to the interpretation of data from constitutive knockouts is the possibility that the loss of one receptor
alters the expression of the other. Indeed, like any lesion study,
knockouts can’t reveal the function of the missing component
but can only reveal the capacity remaining in the absence of that
component. We therefore compared OX1 and OX2 mRNA levels
isolated from whole brainstems of C57BL6 and receptor knockout
mice using quantitative RT-PCR to (Figure 11). Since two splice
variants of the OX2 were identified in mice (Chen and Randeva,
2004; Chen et al., 2006), we designed primers for OX1 and both
OX2 receptors. The primers used for each receptor were specific since PCR produced single amplicons of the predicted sizes.
These amplicons were undetectable in samples from the corresponding single receptor knockout or double receptor knockouts
(Figure 11, see gel insets). Results from ANOVAs comparing target mRNA levels by genotype were highly significant for each
transcript (P < 0.001). Post-hoc testing revealed that the fraction
of OX1 mRNA per total mRNA in brainstems from C57BL6 mice
(9.75E-6 ± 2.00E-6, n = 28 samples from 14 mice) was not dif−/−
brainstems (1.07E-5 ±
ferent from that measured from OX2
1.39E-6, n = 28 samples from 14 mice; P = 0.62; Figure 11A). In
−/−
mice, levels of both the OX2 α
contrast, we found that in OX1
(9.48E-5 ± 2.52E-5, n = 20 samples from 10 mice) and OX2 β
(1.88E-4 ± 3.97E-5, n = 26 samples from 13 mice) splice variants were significantly higher compared to those from C57BL6
mice (OX2 α: 7.16E-6 ± 2.27E-6, n = 14 samples from 7 mice,
P < 0.0001; OX2 β: 1.94E-5 ±3.78E-6, n = 14 samples from 7
mice, P < 0.0005; Figures 11B,C).
Since these differences could indicate upregulation of OX2
expression resulting from the absence of OX1 and since the single receptor knockouts were on a mixed C57BL6 and 129SvEv
background, we also measured receptor levels in 129SvEv mice.
This comparison indicated that levels of OX1 are higher in
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FIGURE 9 | Inhibition of PKC by Bis I attenuated Ca2+ -transients
evoked by activation OX1 or OX2 . (A) Ca2+ transients in LDT, DR,
−/−
mice were attenuated by prior
and LC neurons in slices from OX2
application of Bis I. (B) Similarly, Ca2+ transients in LDT, DR, and LC

−/−

129SvEv brainstems than in either C57BL6 or OX2 brainstems
(2.89E-5 ± 2.04-06, n = 16 samples from 8 mice, P < 0.0001
for both; Figure 9A). Interestingly, levels of OX2 α (4.08E-5 ±
1.46E-5, n = 16 samples from 8 mice) and OX2 β (7.21E-5 ±
3.22E-5, n = 15 samples from 8 mice) from 129SvEv brainstems
were not statistically different from those in C57BL6 brainstems
(OX2 α: P = 0.18; OX2 β: P = 0.17) but were significantly lower
−/−
than those from OX1 brainstems (OX2 α : P < 0.02; OX2 β: P <
0.02; Figures 11B,C). These findings suggest that background
alone is not the reason that OX2 mRNA levels are higher in
−/−
mice and therefore imply some level of
brainstems from OX1
compensation.

DISCUSSION
A major finding of this study is that OX1 exclusively mediates
direct depolarization of nNOS+ LDT and TH+ LC neurons,
while both receptors mediate direct depolarization of TpH+ DR
neurons. In contrast, augmentation of depolarization-induced
Ca2+ transients was mediated by OX1 and OX2 in each nucleus
and likely involved L-type Ca2+ channels and PKC signaling.
Finally, we found whole-brainstem OX2 mRNA levels were ele−/−
mice. These findings have implications for
vated in OX1
understanding the cellular function of native orexin receptors, for
understanding the roles played by orexin signaling at these loci in
the control of behavioral state and for understanding the consequences of using receptor specific antagonists as therapeutics.
Interpretation of our results are predicated on the idea that
the different observed actions of orexin in OX1 null and OX2 null
slices result from the absence of orexin receptors rather than from
differences in genetic background between each mouse. Since
genetic drift occurs and there is allelic variation in each parent
strain, possibly in modifier genes, there is some uncertainty to
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−/−

mice were attenuated by prior application
neurons in slices from OX1
of Bis I. Horizontal bars above the traces indicate application of
orexin-A (300 nM). Calibration bars indicate 20% dF/F and 2 min in each
panel.

this interpretation (Doetschman, 2009). We found that orexin
currents had the same variation of responses and mean amplitude in both C57BL6 mice and in OxrWT, which have the same
mixed genetic background as our knockout mice. In both strains,
slices from each mouse showed responses to orexin and neither strain showed symptoms of narcolepsy (Kalogiannis et al.,
2011) indicating that despite genetic drift and the allelic variations
present, orexin signaling at our targets was equivalent in both
backgrounds. Moreover, in DKO mice there were no response in
any of the cells recorded in any mouse tested, and these mice show
severe signs of narcolepsy (Kalogiannis et al., 2011). These considerations, and the recent evidence that the distribution of orexin
receptor mRNA is not altered in LDT, DR, or LC in orexin receptor knockouts (Mieda et al., 2011) suggest it is unlikely that the
absence of orexin responses result from background effects rather
than the loss of the receptor. We therefore interpret our data in
terms of receptor loss, mindful of the possibility that responses
might also be modulated by background effects.
BOTH NATIVE OREXIN RECEPTORS CAN COUPLE TO A NOISY CATION
CURRENT AND L-TYPE Ca2+ CHANNELS

Recordings from DR neurons in slices from mice lacking either
OX2 or OX1 revealed that activation of either receptor evoked
a noisy inward current appearing identical to the cation current evoked in wild-type slices (Brown et al., 2002; Liu et al.,
2002; Kohlmeier et al., 2008). Since orexin-A did not activate
this current in slices lacking both receptors, we conclude that
signaling by either receptor converges onto this current and
that there are no additional orexin-binding receptors sufficient
to mediate this action. The ability of both receptors to augment depolarization-induced Ca2+ transients mediated by L-type
Ca2+ channels via a PKC-sensitive pathway further supports
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FIGURE 10 | Orexin fails to produce Ca2+ transients in slices from DKO
mice. (A) Somatic dF/F signals recorded from fura-2AM loaded LDT, DR,
and LC cells in slices from DKO mice. Orexin-A application did not produce
detectable changes in dF/F for any recorded cell. (B) Bolus application of
glutamate (5 mM; delivered at arrow) produced strong Ca2+ transients in
the same cells indicating that they remained viable. Horizontal bars above
the traces indicate application of orexin-A (Orx-A; 300 nM). Calibration bars
indicate 50% dF/F and 2 min in (A) and 50% dF/F and 1 min in (B).

convergent or redundant functions of native OX1 and OX2 in
DR neurons. Immunofluorescence identification demonstrated
that this convergence includes serotonergic DR neurons (TpH+).
These findings fit well with double in-situ hybridization evidence
indicating both receptors are co-localized within a large fraction
of TpH-expressing neurons in mouse DR (Mieda et al., 2011), and
with single-cell RT-PCR evidence indicating both OX1 and OX2
mRNA is typically recovered from TpH neurons in rat (Brown
et al., 2002). Together, these data suggest that both orexin receptors normally excite TpH neurons and augment their intracellular
Ca2+ -levels during periods of prolonged depolarization.
Since the average OX1 –evoked inward current was somewhat
larger than the OX2 –evoked current, and since OX1 activation
produced Ca2+ transients in a greater fraction of DR neurons
than did OX2 activation, it is plausible that OX1 normally mediates the larger part of the orexin-mediated depolarization of
DR neurons. A previous pharmacological study of rat DR slices
concluded that OX2 is primarily responsible for orexin-evoked
spiking (Soffin et al., 2004). However, that conclusion was based
on data that was acknowledged to be difficult to interpret and
suffered from limitations related to the use of selective agonists for receptor subtype identification (see also Leonard and
Kukkonen, 2013). Co-expression and convergent action of these
receptors also likely contributed to interpretive difficulties (e.g.,
the relatively weak effect of the OX1 -selective antagonist SB
334867). Use of conditional receptor knockouts and development
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of subtype-specific receptor antagonists should help to further
clarify the natural role of each receptor.
In contrast to the DR, OX1 was necessary for orexin to elicit
depolarizing currents in principal LDT and LC neurons, which
fits well with the high levels of OX1 mRNA in these structures
from adult rodents (Marcus et al., 2001; Mieda et al., 2011). Since
OX2 is competent to activate a similar depolarizing current in DR
neurons, it is possible that OX2 is either not expressed, or is incapable of activating available depolarizing channels in LDT and LC
neurons. Isotopic in-situ hybridization indicates OX2 message is
much less abundant than OX1 but is above background in both
the LDT and LC (Marcus et al., 2001), suggesting that low levels of
OX2 are present. Recent double, non-isotopic, in-situ hybridization studies detected OX2 only in non-cholinergic LDT neurons
and non-TH+ LC neurons (Mieda et al., 2011). Nevertheless,
we found clear examples of LDT and LC neurons where orexinA enhanced depolarization-induced Ca2+ transients in OX1 null
slices, albeit fewer LDT and LC neurons were activated compared to slices from wild-type or OX2 null mice (Figure 8).
Moreover, we recovered nNOS+ and TH+ neurons showing
orexin-augmented Ca2+ -transients, indicating that OX2 signaling
influences at least a sub-population of these neurons (Figure 6).
These latter findings are consistent with the possibility that OX2
expression in LDT and LC neurons might be developmentally regulated and could be lower in adult mice compared to the 2–4
week-old-mice used here, or simply that functional OX2 receptors
are present, but that mRNA levels are too low to be detected with
double in-situ hybridization methods, which are generally less
sensitive than isotopic methods. If this is the case, how then does
OX2 augment the depolarization-induced Ca2+ influx without
also producing a depolarization? One possibility is that there is
spatial segregation of OX1 and OX2 and their respective effectors
such that OX2 signaling can’t activate the depolarization channels.
Another possibility is that each receptor activates different second
messenger cascades and the depolarizing channels in LDT and
LC are only activated by the cascade(s) from OX1 . Neither scenario has been demonstrated for native orexin receptors and both
deserve further investigation. In general, the messenger cascades
underlying native orexin receptor actions are poorly understood,
although they appear more diverse that originally thought (for
review see Kukkonen and Leonard, 2013). Moreover, the cascades mediating depolarization in these neurons have not been
identified, although since PKC is involved with augmenting Ca2+ transients, both receptors may activate PLC, as has been often
found elsewhere (for review see Kukkonen and Leonard, 2013).
While the cation currents activated in LDT and DR appear quite
similar, we did find previously that low-Ca2+ ACSF augments the
DR current, but not the LDT current (Kohlmeier et al., 2008),
suggesting the possibility that different channels may mediate the
orexin-activated cation current in these neurons. Future experiments are needed to clarify the signaling pathways and effectors
utilized by each receptor in these neurons.
Finally, it is also possible that the orexin-enhanced Ca2+ transients were produced indirectly by an unknown mediator released
from OX2 -expressing nNOS- and TH- neurons in response to
orexin-A. This seems unlikely since blocking action potentials
with TTX, did not attenuate the orexin effects. However, this is
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FIGURE 11 | Levels of whole brainstem OX2 mRNA are higher in
−/−
mice compared to wild-type mice. (A–C) Top Gel images
OX1
of the amplicons resulting from probes for OX1 (A), OX2 α (B), and
OX2 β (C). Samples for each lane were 1: blank, 2–5: scales for
−/−
−/−
sample, 8: OX2
corresponding receptor, 6: C57 sample, 7: OX1
sample, 9: DKO sample. (A) Bottom RNA for OX1 (OX1 per total)
was quantified from whole brainstems of C57BL6(C57; 28 samples
−/−
−/−
(9 samples from 5 mice), OX2
(28
from 14 mice), OX1
samples from 14 mice), double orexin receptor knockouts (DKO; 8
samples from 4 mice) and 129SvEv (129s; 16 samples from 8 mice)
mice by RT-PCR. OX1 mRNA was undetectable in tissue from
OX1−/− and DKO mice. Despite significantly higher levels of OX1
−/−
mRNA in brainstems from 129s mice compared to C57 and OX2
brainstems (∗ P < 0.0001), there was no significant difference between

difficult to rule out since conventional procedures to block Ca2+ dependent release, like lowering extracellular Ca2+ or adding
Co2+ or Cd2+ , also block the Ca2+ influx we monitored. Future
studies using acutely isolated neurons could help address this
issue.
ROLES OF OREXIN SIGNALING IN RETICULAR ACTIVATING SYSTEM
NEURONS

Our main finding demonstrates that OX1 is required for orexinmediated excitation of LC and LDT neurons but that either
receptor is sufficient to mediate excitation of DR neurons. While
subtle developmental changes in orexin receptor distribution cannot be ruled out, this main finding, obtained from young mice,
agrees very well with orexin receptor mRNA levels in these neurons from adult mice (Mieda et al., 2011). It is therefore possible
to compare the impairment of excitation observed here to the
degree of behavioral impairment reported for each knockout, in
order to gain insight into the functional consequences of orexin
receptor signaling at these loci. Deletion of both receptors produces a narcolepsy phenotype (Hondo et al., 2010; Kalogiannis
et al., 2011) similar to that seen in the prepro-orexin knockouts
(Chemelli et al., 1999; Mochizuki et al., 2004), with fragmented
waking states, spontaneous sleep attacks and frequent cataplexy.
Since orexin-A normally stimulates a large fraction of LDT, DR,
and LC neurons, the loss of orexin action at these sites in the
DKOs is consistent with a role for orexin signaling at these loci
in promoting wake and sleep consolidation, suppressing REM
sleep, preventing sleep attacks and suppressing cataplexy. Indeed,
optogenetic excitation of orexin neurons promotes sleep-to-wake
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−/−

mRNA levels measured in brainstems from C57 and OX2
mice. (B)
Bottom mRNA levels for OX2 α (OX2 α per total) were measured from
isolates obtained from the same mice used in (A). OX2 α mRNA
−/−
(7 samples from 4 mice)
was undetectable in tissue from OX2
and DKOs (20 samples from 10 mice). OX2 α mRNA levels were
−/−
samples (20 samples from 10 mice) than in either
higher in OX1
C57 (14 samples from 7 mice) or 129s (16 samples from 8 mice)
samples (∗ P < 0.02). (C) Bottom Similarly, mRNA levels for OX2 β
(OX2 β per total) were measured from mRNA isolates from the same
−/−
(14
mice in A. OX2 β mRNA was undetectable in tissue from OX2
samples from 7 mice) and DKOs (20 samples from 10 mice). OX2 β
−/−
mice (26 samples
mRNA levels were higher in tissue from OX1
from 13 mice) than in tissue from either C57 (14 samples from 7
mice) or 129s mice (15 samples from 8 mice, ∗ P < 0.02).

transitions (Adamantidis et al., 2007) and optogenetic inhibition
of orexin neurons promotes slow-wave sleep and reduced firing of
DR neurons (Tsunematsu et al., 2011), while focal orexin injection into the LDT (Xi et al., 2001) or LC (Bourgin et al., 2000)
prolongs waking bouts and suppresses REM sleep. Moreover,
optogenetic inhibition of TH+ LC neurons blocks the ability
of orexin neuron stimulation to promote sleep-to-wake transitions (Carter et al., 2012), while ontogenetic stimulation of
TH+ LC neurons both prolongs waking (Carter et al., 2010) and
enhances the wake-promoting effect of orexin neuron stimulation (Carter et al., 2012). This indicates orexin–excitation of TH+
LC neurons is necessary for orexin neuron activity to promote
sleep-to-wake transitions. Nevertheless, it is the OX2 knockouts
that show fragmented spontaneous waking and sleep states and
have sleep attacks at the same frequency as prepro-orexin knockouts (Willie et al., 2003), even though orexin-mediated excitation
of LDT, DR, and LC neurons is preserved (Figure 2). This might
indicate that orexin neuron firing and orexin release is impaired
through the loss of OX2 -mediated positive feedback (Yamanaka
et al., 2010) and/or that residual OX1 -excitation of LDT, DR, and
LC neurons is insufficient to maintain normal duration bouts
of spontaneous waking and sleep in the absence of OX2 , even
though ICV orexin still prolongs waking and suppresses REM
−/−
−/−
mice (Mieda et al., 2011). Conversely, OX1
sleep in OX2
mice appear to have normal sleep-wake states without fragmentation or sleep attacks (Hondo et al., 2010; Mieda et al., 2011),
even though orexin excitation is abolished in LDT and LC neurons and is reduced in DR neurons (Figure 5), in spite of possible
upregulation of OX2 (Figure 11). Thus, it appears intact orexin
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excitation in the LDT, DR, and LC is neither necessary nor
sufficient for the expression of normally consolidated bouts of
spontaneous sleep and waking. Since, OX1 signaling in LDT,
DR, and LC promotes arousal, but is not necessary for consolidated spontaneous waking, orexin signaling at these loci may
promote context-dependent arousal associated with, for example, stress, anxiety, panic, and/or food and drug seeking behavior
(Winskey-Sommerer et al., 2004; Boutrel et al., 2005; Harris et al.,
2005; Nair et al., 2008; Johnson et al., 2012; Piccoli et al., 2012;
Steiner et al., 2012; Heydendael et al., 2013). Orexin signaling
at these loci may also support other functions. For example,
−/−
OX1
mice show impaired acquisition and expression of cued
and contextual fear conditioning and the re-expression of OX1
in TH+ LC neurons rescues the expression of cued fear (Soya
et al., 2013). Future studies using receptor rescue approaches
(Mochizuki et al., 2011) or the local application of OX1 -specific
antagonists will be needed to further explore OX1 functions at
these loci.
Our findings are also consistent with a cataplexy-suppressing
−/−
mice
role for orexin excitation in the LDT, DR and LC. OX2
have cataplexy but it occurs rarely compared with prepro-orexin
null mice (Willie et al., 2003). Since DKO mice show frequent
cataplexy-like arrests (Kalogiannis et al., 2011), the less severe
−/−
mice is likely related to residual OX1 sigcataplexy in OX2
naling. Since orexin injections into the LDT and LC suppress
REM sleep, and knockdown of OX1 in LC increases REM during
the dark phase (Chen et al., 2010) it is plausible that remaining
OX1 -excitation in LDT, LC, and perhaps DR, reduces cataplexy in
−/−
−/−
OX2
mice. Nevertheless, OX1
mice do not have cataplexy,
indicating that the loss of orexin-excitation in LDT and LC and
reduced orexin excitation in the DR is not sufficient to produce
cataplexy, at least in these knockouts, where OX2 may also be up
regulated.
IMPLICATIONS FOR SINGLE OREXIN RECEPTOR
PHARMACOTHERAPEUTICS

DORAs show significant promise for improved treatment of
insomnia (Uslaner et al., 2013; Winrow and Renger, 2013) and
are currently being considered for FDA approval. Given that orexins regulate numerous functions beyond normal waking and sleep
and that their receptors are differentially distributed, it seems
likely that subtype-specific orexin receptor antagonists (SORAs)
will have even greater therapeutic potential. The development
of sub-type specific drugs will accelerate preclinical investigations of receptor function and, may allow better targeting of
different orexin-dependent behaviors and a fine-tuning of their
sleep-promoting effects. For example, OX2 antagonists appear
more effective at sleep promotion than DORAs (Dugovic et al.,
2009), perhaps by targeting hypothalamic circuits promoting histamine release and consolidated waking (Dugovic et al., 2009;
Mochizuki et al., 2011). Conversely, OX1 antagonists may provide
better relief for hyperarousal and other maladaptive behaviors
associated with stress, as noted above, perhaps by dampening OX1
excitation of noradrenergic, serotonergic and cholinergic reticular neurons and midbrain dopamine systems. Nevertheless, much
more needs to be learned about how each orexin receptor impacts
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their cellular targets and how these targets influence behavior.
These interactions are likely to be complex: as demonstrated here
for key elements of the reticular activating system, each receptor can have common effectors (i.e., both receptors activating
depolarizing channels and enhancing voltage-dependent Ca2+
transients in TpH DR neurons) or act differentially with respect
to one effector while having a common action on another effector (i.e., OX1 is necessary for depolarization while both receptors
enhance voltage-dependent Ca2+ transients in LDT and LC neurons). It will also be important in future experiments to evaluate
the degree to which persistent alteration of signaling by either
orexin receptor impacts synaptic plasticity (Borgland et al., 2006;
Selbach et al., 2010), neurotransmitter phenotypes (Kalogiannis
et al., 2010; Valko et al., 2013) and orexin receptor expression
(i.e., elevated brainstem OX2 message levels in OX1 null mice), as
each of these could lead to deleterious side-effects and diminished
therapeutic potential.
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